Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting 2021

3D-Bioprinting 2021 Agenda



Co-Located Conference Agendas

3D-Bioprinting 2021 | Innovations in Microfluidics 2021 | 

Print Agenda

Thursday, 18 March 2021


Please View Details of Day 1 of the Event Under the Innovations in Microfluidics Track Agenda Section

Friday, 19 March 2021

08:00

Morning Coffee, Pastries and Networking


Session Title: 3D-Printing, circa 2021

09:00

Marc FerrerKeynote Presentation

Bioengineered Tissue Models for Drug Discovery and Development
Marc Ferrer, Director, 3D Tissue Model Laboratory, NIH/NCATS, United States of America

Tissue equivalents produced using bioengineering technologies are emerging as robust and versatile cellular assay platforms for drug discovery and development.  Bioengineering technologies enable the production of spatially controlled tissues with tailored physiological complexity using iPSC-derived or primary cells, in multi-well plate platforms amenable for medium throughput screening.

Operationalization of the use of bioengineered 3D organotypic models with existing automation screening platforms meets with challenges in cell production, reproducible tissue biofabrication in multi-well plate format, 3D phenotypic assays, and data generation and processing challenges.  Examples of bioengineered tissue models and their use for drug screening will be discussed.

09:45

Stephanie WillerthKeynote Presentation

3D Bioprinting Personalized Neural Tissues For Drug Screening
Stephanie Willerth, Professor and Canada Research Chair in Biomedical Engineering, University of Victoria and CEO – Axolotl Biosciences, Canada

3D bioprinting can create living human tissues on demand based on specifications contained in a digital file. Such highly customized, physiologically-relevant 3D human tissue models can screen potential drug candidates as an alternative to expensive pre-clinical animal testing. The Willerth lab has developed a novel fibrin-based bioink for bioprinting neural tissues derived from human induced pluripotent stem cells (hiPSCs), which can become any cell type found in the body. Here I will discuss the latest work from our group detailing the composition of our 3D bioprinted tissues and our new spin-off company - Axolotl Biosciences.

10:30

Morning Coffee Break and Networking

11:00

DPS GroupEquipment and Facility Considerations for 3D Bioprinting Based Production
William Whitford, Life Science Strategic Solutions Leader, DPS Group

Both 3D bioprinting technologies and applications are developing at an extremely fast pace. Diverse analytical and diagnostic products made using bioprinting technologies include microfluidic devices, organ-on-a-chip systems, and 3D in vitro tissue models for both drug research and clinical diagnostics. Therapeutic products are also beginning to be developed and these include bioprinted patches, tissues systems, and even organs. For the regulation of these products, the US FDA has spoken on the issue of the certification of 3D printed medical devices and have indicated they intend to codify issues related to bioprinting.  However, 3D printing technology is so dynamic that basic questions remain regarding practical and comprehensive requirements for the manufacturing of 3D bioprinted products or 3DBP (and personalized 3DBP), diagnostic and therapeutic materials, devices and cell therapies.  Facility and work-flow solutions are dependent upon many process design and compliance factors.  As technological and regulatory obstacles are being removed, the development of biomanufacturing operations raises new considerations. These considerations will include whether the 3DBP is traditional, patient-specific or customizable as well as hospital-made or mass produced.  The following will therefore include current thoughts on materials, equipment, facilities and workflows for the production and manufacturing of 3DBP.

11:30

Ibrahim OzbolatKeynote Presentation

3D Bioprinting of Living Tissues and Organs: From Basic Science to Clinical Translation
Ibrahim Ozbolat, Hartz Family Associate Professor of Engineering Science and Mechanics, The Huck Institutes of the Life Sciences, Penn State University, United States of America

3D Bioprinting is a disruptive technology enabling deposition and patterning of living cells in order to manufacture replacement tissues and organs for tissue engineering, regenerative medicine, disease modeling and drug screening purposes. In this talk, Dr. Ozbolat will survey the emerging field of bioprinting and its impact on medical sciences. In the first part of his seminar, he will present a wide range of 3D bioprinting efforts in manufacturing of tissue/organ substitutes performed in his laboratory in the last nine years. In the second part, he will present a new bioprinting technique, called aspiration-assisted bioprinting, and explain the underlying physical mechanism in order to understand the interactions between physical governing forces and aspirated viscoelastic tissue building blocks. Finally, he will demonstrate a new intraoperative bioprinting approach in order to repair composite soft/hard tissues during craniofacial reconstruction on a rat model in a surgical setting.

12:15

A 3D Bioprinted Human Neurovascular Unit as a Tissue-in-a-well Platform For Brain Disease Modeling and Drug Screening
Yen-Ting Tung, Research Fellow, National Center for Advancing Translational Sciences (NCATS), United States of America

A 3D bioprinted human neurovascular unit (NVU) was developed in a 96-multiwell plate format for using as a tissue-in-a-well assay platform for high through-put screening.

12:45

Networking Lunch in the Exhibit Hall for the Physical On-Site Participants

14:00

Joyce WongKeynote Presentation

Pediatric Vascular Tissue Engineering
Joyce Wong, Professor of Biomedical Engineering and Materials Science & Engineering, Boston University, United States of America

This presentation will describe different technologies including 3D printing and cell sheet technology development with the aim of creating blood vessel patches for pediatric vascular tissue engineering.

14:45

Noah MalmstadtKeynote Presentation

Designing a Bioreagent-Compatible Material for a 3D-Printed Molecular Design System
Noah Malmstadt, Professor, Mork Family Dept. of Chem. Eng. & Mat. Sci., University of Southern California, United States of America

While stereolithographic 3D printing (SLA) is a promising method for the rapid prototyping and manufacturing of microfluidic systems, the bioadhesive properties of cured SLA resins are poorly characterized. Adhesion of biomolecules to microfluidic channels is an issue in nearly all biological applications, but it becomes a particular problem in applications that require precise and reproducible control of reaction conditions. Over the past several years, we have deployed SLA-printed modular microfluidic components to automate the biochemical workflow of mRNA display. mRNA display is a selection technology that harnesses a massive oligonucleotide-peptide hybrid library to identify molecules that bind to protein targets; automating the mRNA display workflow is a route towards the rapid development of novel cancer protein binding agents. A major roadblock to the microfluidic automation of mRNA display is the nonspecific adhesion of the many required enzyme, peptide, and oligonucleotide reagents to the channel surfaces.

To minimize or eliminate this adhesion, we have explored a range of SLA resin formulations based on vinyl monomers with various functional groups. After examining the achievable resolution and mechanical properties of each formulation, we characterized peptide, oligonucleotide, and protein adhesion and determined the degree to which adhered enzymes retained enzymatic activity. Low-adhesion SLA-printed modules were assembled to construct an automated system capable of producing new mRNA display binding ligands.

15:30

Wai Yee YeongKeynote Presentation

3D-Bioprinting of Soft Tissues: Functions and Processes
Wai Yee Yeong, Programme Director and Associate Professor, Nanyang Technological University, Singapore

The bioprinting landscape is expanding and growing with exciting new advances. Different bioprinting methods have been proposed to achieve functional and biological applications from the assembly of bioactive elements. In this talk, we will focus on 3D bioprinting of soft tissues with the focus on the key functional aspects of using 3D bioprinting. Beyond just creating the shapes, 3D bioprinting process is an innovative tool for aligning cells and recreating biomimetic design of soft tissues.

16:15

David L. KaplanKeynote Presentation

Title to be Confirmed.
David L. Kaplan, Stern Family Endowed Professor of Engineering, Professor & Chair -- Dept of Biomedical Engineering, Tufts University, United States of America

17:00

Close of Day 2 of the Conference


Add to Calendar ▼2021-03-18 00:00:002021-03-19 00:00:00Europe/London3D-Bioprinting 20213D-Bioprinting 2021 in BostonBostonSELECTBIOenquiries@selectbiosciences.com